CryoLife announces definitive agreement to acquire On-X Life Technologies Holdings, Inc.

Wednesday, December 23, 2015

CryoLife, Inc., a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has entered into a definitive agreement to acquire On-X Life Technologies Holdings, Inc. ("On-X"), an Austin, Texas-based, privately held mechanical heart valve company.

J. Patrick Mackin, Chairman, President, and Chief Executive Officer of CryoLife, said, "We believe this will be a transformative acquisition for CryoLife that will significantly enhance the size of our addressable market and growth potential.  This transaction will provide CryoLife access to the $220 million mechanical valve market with a highly advanced portfolio of products.  On-X valves have been implanted in over 200,000 patients, and On-X has achieved a 13% revenue CAGR over the past four years with modest sales and marketing support.  We are very excited about the outlook for continued growth for several reasons.  First, the On-X aortic valve is the only mechanical valve to receive FDA labeling requiring an INR (international normalized ratio) level of only 1.5-2.0.  This labeling provides the On-X valve with a distinct competitive advantage.  Second, with the addition of the On-X sales team to the CryoLife team, our U.S. cardiac surgery sales force will more than double.  Third, as the power of On-X's technology and its supporting robust clinical data become more widely known through our expanded sales organization, we believe the acquired portfolio will continue to post double-digit compounded growth from 2016-2020.  Finally, we believe we will also see strong synergy between our product portfolios, which will drive cross-selling opportunities across our entire business."

Clyde Baker, President and Chief Executive Officer of On-X, commented, "On-X is  extremely excited to join forces with CryoLife and we believe CryoLife is well suited to take the On-X business to the next level.  We expect this transaction to enhance the growth trajectory of On-X products through the additional resources provided by a larger, global cardiac surgery company."

On-X generated revenue of approximately $33 million in 2014, representing compound annual growth of approximately 13% over the preceding four years.

 

cryolife.com

TOP